EUCTR2020-000791-38-NL进行中（未招募）1 期
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 658
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 40–85 years
- •Documented diagnosis of IPF per the 2018 American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Society Clinical Practice Guideline
- •High-resolution computed tomography pattern consistent with the diagnosis of IPF, confirmed by central review of Chest HRCT and central review of any available lung biopsy (LB)
- •Minimum 6MWD of 150 meters with maximum use of 6 L/min at sea-level and up to 8 L/min at altitude of supplemental oxygen while maintaining oxygen saturation of >= 83% during the 6MWT during screening
- •FVC >= 45% predicted during screening as determined by the over-reader
- •Forced expiratory volume in 1 second (FEV1)/FVC ratio > 0.70 during screening as determined by the over-reader
- •DLCO >= 30% and <= 90% of predicted during screening (Hgb corrected or uncorrected) as determined by the over-reader
- •If receiving pirfenidone or nintedanib treatment for IPF, the patient must have been on treatment for at least 3 months and on a stable dose for at least 4 weeks prior to screening and during screening
- •If not currently receiving nintedanib or pirfenidone treatment must have discontinued such treatment >= 4 weeks prior to screening and during screening
- •For women of childbearing potential (excluding patients enrolling in Japan): agreement to remain abstinent or use contraception, women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 8 weeks after the final dose of PRM-151
- •For men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm, with a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 8 weeks after the final dose of PRM-151 to avoid exposing the embryo. Men must refrain from donating sperm during this same period
- •Anticipated life expectancy of at least 12 months at baseline, according to the investigator’s judgment
- •Patient and investigator considered all medicinal treatment options and/or possibly lung transplantation prior to considering participation in the study. If the patient is on a lung transplant list, the investigator anticipates the patient will be able to complete the study prior to transplant
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 178
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 480
排除标准
- •Evidence of other known causes of interstitial lung disease
- •FVC% predicted value showing improvement in the 6-month period prior to screening and including screening value, as assessed by the investigator • Emphysema present on >= 50% of the HRCT, or the extent of emphysema is greater than the extent of fibrosis, according to central review of the HRCT
- •Receiving nintedanib in combination with pirfenidone
- •Received cytotoxic, immunosupressive, cytokine modulating, or receptor antagonist agents within 4 weeks prior to or during screening
- •Receiving systemic corticosteroids equivalent to prednisone > 10 mg/day or equivalent within 2 weeks prior to or during screening
- •Receiving strong inhibitor or inducer of CYP1A2 in patients taking pirfenidone
- •Receiving potent inhibitor or inducer of P-gp in patients taking nintedanib
- •Acute respiratory or systemic bacterial, viral, or fungal infection either during screening or prior to screening and not successfully resolved 4 weeks prior to screening visit
- •Positive interferon gamma release assay
- •Test for tuberculosis during screening: Patients who have completed treatment for active or latent tuberculosis within 6 months prior to screening, and have no evidence of recurrent disease, do not need to be tested
- •Resting oxygen saturation of < 89% using up to 4 L/min of supplemental oxygen at sea level and up to 6 L/min at altitude during screening
- •Co-existing acute or chronic medical condition that, in the investigator’s opinion, would substantially limit the ability to comply with study requirements or may influence any of the safety or efficacy assessments included in the study
- •Class IV New York Heart Association chronic heart failure
- •Historical evidence of left ventricular ejection fraction < 35%
- •Presence of pulmonary hypertension that, in the investigator’s opinion, would substantially limit the ability to comply with study requirements or may influence any of the safety or efficacy assessments included in the study
- •Cardiopulmonary rehabilitation program based on exercise training that has been completed within 8 weeks prior to screening or planned to start during the patient’s enrollment in this trial
- •History of smoking (including cigarette, cannabis, cigar, pipe and vaping) within 3 months prior to or during screening
- •History of alcohol or substance use disorder within 2 years prior to or during screening or known or suspected active alcohol or substance-use disorder
- •History of a malignancy within the 5 years prior to screening, with the exception of basal cell or squamous cell skin neoplasms. In addition, a malignant diagnosis or condition that occurred more than 5 years prior to screening, and any basal cell or squamous cell neoplasm must be considered cured, inactive, and not under treatment
- •Unable to refrain from use of the following:
- •– Short acting bronchodilators (SABA) within 4 hours before pulmonary function, DLCO, and 6MWT assessments
- •– Once daily, long-acting bronchodilators within 24 hours before pulmonary function, DLCO, and 6MWT assessments
- •– Twice daily, long-acting bronchodilators within 12 hours before pulmonary function testing, DLCO, and 6MWT assessments
- •Known post-bronchodilator response in FEV1 and/or FVC >= 12% and >= 200 mL, respectively
- •Receipt of an investigational drug within 4 weeks, or 5 half-lives, whichever is longer, prior to or during screening
- •Previous treatment with PRM-151
- •History of severe allergic reaction or anaphy
研究者
相似试验
招募中
不适用
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY IN ADULTS TO DETERMINE THE SAFETY, EFFICACY, ANDIMMUNOGENICITY OF AZD1222, A NON-REPLICATING CHADOX1 VECTOR VACCINE, FOR THE PREVENTION OF COVID-19-J98J98PER-059-20AstraZeneca AB,1,470
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerFirst line of treatment for Estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: LLTClassification code 10070577Term: Oestrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10083232Term: HER2 negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000119-66-ATF. Hoffmann-La Roche Ltd978
进行中（未招募）
3 期
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerPATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCEJPRN-jRCT2071200038Clinical trials information992
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of PRM-151 in Patients with Idiopathic Pulmonary FibrosisIdiopathic pulmonary fibrosis (IPF)MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-000791-38-NOF. Hoffmann-La Roche Ltd658
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerFirst line of treatment for Estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: LLTClassification code 10070577Term: Oestrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10083232Term: HER2 negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000119-66-DEF. Hoffmann-La Roche Ltd978